Kotak Darsheen, Attar Esha, Dalal Bhavik, Shankarkumar Aruna, Devarajan Padma
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, N.P. Marg, Matunga (E), Mumbai, 400019, Maharashtra, India.
Department of Transfusion Transmitted Disease, ICMR-National Institute of Immunohematology, KEM Hospital Campus, Parel, Mumbai, 400012, Maharashtra, India.
AAPS PharmSciTech. 2025 Mar 18;26(4):88. doi: 10.1208/s12249-025-03068-w.
We earlier reported comparable efficacy in bone parameters of sublingually administered salmon calcitonin hydroxyapatite nanoparticles (SCT-HAP-NPs) compared to the subcutaneous injection, in the ovariectomy rat model, despite a bioavailability of barely ~ 15%. We ascribed this intriguing finding to targeted bone delivery, facilitated by translocation of significant quantity of intact NP into systemic circulation. In the present study we track the translocation of FITC-SCT-HAP-NPs (~ 100 nm) across porcine sublingual mucosa using the Franz diffusion cell to validate our hypothesis. Confocal Laser Scanning microscopy (CLSM) established that SCT-HAP-NPs permeated into the deeper layers of sublingual porcine mucosal tissue. We confirmed the nanoparticles were present in the receptor medium of the Franz diffusion cell by DLS and TEM. We also demonstrate for the first time quantification of the NPs (%) translocated across the porcine mucosa, using the Amnis Image StreamX Mk II imaging flow cytometer. Computation revealed transport of ~ 60% of the FITC-SCT-HAP-NPs across mucosa in 2 h, substantiated that high NP concentrations could reach systemic circulation. Such high NP concentration in systemic circulation coupled with the small size (~ 100 nm) and the high bone affinity of HAP, validate our hypothesis of targeted bone delivery following sublingual administration. Furthermore, quantification of translocated NPs, which we demonstrate for the first time, would permit rational development of optimal targeted nanoparticulate carriers for delivery by noninvasive routes.
我们之前报道,在卵巢切除大鼠模型中,经舌下给药的鲑鱼降钙素羟基磷灰石纳米颗粒(SCT-HAP-NPs)与皮下注射相比,在骨参数方面具有相当的疗效,尽管其生物利用度仅约为15%。我们将这一有趣的发现归因于靶向骨递送,这是由大量完整纳米颗粒转运至体循环所促成的。在本研究中,我们使用Franz扩散池追踪异硫氰酸荧光素标记的SCT-HAP-NPs(约100纳米)穿过猪舌下黏膜的转运情况,以验证我们的假设。共聚焦激光扫描显微镜(CLSM)证实SCT-HAP-NPs渗透到猪舌下黏膜组织的深层。我们通过动态光散射(DLS)和透射电子显微镜(TEM)确认纳米颗粒存在于Franz扩散池的受体介质中。我们还首次使用Amnis Image StreamX Mk II成像流式细胞仪对穿过猪黏膜的纳米颗粒(%)进行了定量。计算结果显示,约60%的异硫氰酸荧光素标记的SCT-HAP-NPs在2小时内穿过黏膜,证实高浓度的纳米颗粒能够到达体循环。体循环中如此高浓度的纳米颗粒,再加上其小尺寸(约100纳米)和羟基磷灰石对骨的高亲和力,验证了我们关于舌下给药后靶向骨递送的假设。此外,我们首次展示的对转运纳米颗粒的定量,将有助于合理开发用于非侵入性给药途径的最佳靶向纳米颗粒载体。